Pasadena’s Arrowhead Pharmaceuticals Now Listed on Standard & Poors Index

Published : Tuesday, May 28, 2019 | 5:05 AM

Arrowhead Pharmaceuticals Inc., headquartered in Pasadena, has moved into the Standard and Poors Small Cap 600, replacing The Navigators Group which S&P said is set to be acquired by The Hartford Financial Services Group.

The S&P Dow Jones Indices announced the change was effective before the opening of trading Friday, May 24. The announcement said Arrowhead Pharmaceuticals has been added to the S&P Small Cap 600 GICS Biotechnology Sub-Industry index.

News of the move sent Arrowhead Pharmaceuticals shares rallying 12.7 percent the next day, Tuesday, May 21, although the company’s stock has been surging higher since the start of 2018 because of optimism that a reboot of its trademark RNA interference platform will pan out.

Arrowhead Pharmaceuticals, which has its headquarters at 225 South Lake Avenue Suite 1050 in Pasadena, develops medicines that treat intractable diseases by silencing the genes that cause them.

Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism, or RNAi, to induce rapid, deep and durable knockdown of target genes. RNAi, present in living cells, inhibits the expression of a specific gene, thereby affecting the production of a specific protein.

To learn more about Arrowhead Pharmaceuticals Inc., visit

blog comments powered by Disqus